

**PIAS2 (PIASx1) Antibody (C-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP1248a****Specification**

---

**PIAS2 (PIASx1) Antibody (C-term) Blocking peptide - Product Information**Primary Accession [O75928](#)**PIAS2 (PIASx1) Antibody (C-term) Blocking peptide - Additional Information**

Gene ID 9063

**Other Names**

E3 SUMO-protein ligase PIAS2, 632-, Androgen receptor-interacting protein 3, ARIP3, DAB2-interacting protein, DIP, Msx-interacting zinc finger protein, Miz1, PIAS-NY protein, Protein inhibitor of activated STAT x, Protein inhibitor of activated STAT2, PIAS2, PIASX

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP1248a](/product/products/AP1248a) was selected from the C-term region of human PIASx1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**PIAS2 (PIASx1) Antibody (C-term) Blocking peptide - Protein Information****Name** PIAS2**Synonyms** PIASX**Function**

Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulator in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. The effects of this transcriptional coregulation, transactivation or silencing may vary depending upon the biological context and the PIAS2 isoform studied. However, it seems to be mostly involved in gene silencing. Binds to sumoylated ELK1 and enhances its transcriptional activity by preventing recruitment of HDAC2 by ELK1, thus reversing SUMO-mediated repression of ELK1 transactivation activity. Isoform

PIAS2-beta, but not isoform PIAS2-alpha, promotes MDM2 sumoylation. Isoform PIAS2-alpha promotes PARK7 sumoylation. Isoform PIAS2-beta promotes NCOA2 sumoylation more efficiently than isoform PIAS2-alpha. Isoform PIAS2-alpha sumoylates PML at 'Lys-65' and 'Lys-160'.

#### **Cellular Location**

Nucleus speckle {ECO:0000250|UniProtKB:Q8C5D8}. Nucleus, PML body. Nucleus.  
Note=Colocalizes at least partially with promyelocytic leukemia nuclear bodies (PML NBs) (PubMed:22406621) Colocalizes with SUMO1 in nuclear granules (By similarity) {ECO:0000250|UniProtKB:Q8C5D8, ECO:0000269|PubMed:22406621}

#### **Tissue Location**

Mainly expressed in testis. Isoform 3 is expressed predominantly in adult testis, weakly in pancreas, embryonic testis and sperm, and at very low levels in other organs

### **PIAS2 (PIASx1) Antibody (C-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **PIAS2 (PIASx1) Antibody (C-term) Blocking peptide - Images**

### **PIAS2 (PIASx1) Antibody (C-term) Blocking peptide - Background**

PIASX functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. This protein plays a crucial role as a transcriptional coregulator in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. The effects of this transcriptional coregulation, transactivation or silencing may vary depending upon the biological context and the PIAS2 isoform studied. However, it seems to be mostly involved in gene silencing. PIASX binds to sumoylated ELK1 and enhances its transcriptional activity by preventing recruitment of HDAC2 by ELK1, thus reversing SUMO-mediated repression of ELK1 transactivation activity. This peptide consists of an epitope specific to PIAS2-alpha. Isoform PIAS2-beta, but not isoform PIAS2-alpha, promotes MDM2 sumoylation. Isoform PIAS2-alpha promotes PARK7 sumoylation. Isoform PIAS2-beta promotes NCOA2 sumoylation more efficiently than isoform PIAS2-alpha.

### **PIAS2 (PIASx1) Antibody (C-term) Blocking peptide - References**

Arora, T., et al., J. Biol. Chem. 278(24):21327-21330 (2003).Wu, S., et al., Oncogene 22(3):351-360 (2003).Liu, B., et al., Proc. Natl. Acad. Sci. U.S.A. 95(18):10626-10631 (1998).Wu, L., et al., Mech. Dev. 65 (1-2), 3-17 (1997).